Medtronic Hires Renowned
Cardiologist as Vice President of Medical Affairs for Coronary
and Peripheral Business
Researcher, Educator and
Innovator Prof. Martin Rothman Assumes New Role with Industry Following
37 Years of Clinical Practice
|
|
December 8, 2009 -- Minneapolis --
Medtronic, Inc. (NYSE: MDT), today announced the hire of Prof. Martin Rothman
as vice president of medical affairs for the company’s coronary and peripheral
vascular business based in Santa Rosa, Calif.
Prof. Rothman will join Medtronic on Jan. 4, 2010, after 37 years of clinical practice in the U.K. as an interventional cardiologist, including 27 years at the London Chest Hospital (Barts and the London NHS Trust), where he has served for more than a decade as director of cardiac research and development. He is world renowned for his contributions to clinical research, training and education, and medical technology innovation in cardiovascular medicine. “Prof. Rothman stands out as a pioneer and leader in interventional cardiology,” said Sean Salmon, vice president and general manager of the Coronary and Peripheral division, part of the CardioVascular business, at Medtronic. “We
look forward to his leadership of our office of medical affairs,
which will benefit from the scientific rigor and keen insights
that he has demonstrated throughout his medical career.” A
regular presenter at medical meetings and author of peer-reviewed
journal articles, Prof. Rothman has conducted scores of clinical
trials related to interventional cardiology. He has participated
as an investigator in studies of Medtronic’s Endeavor® drug-eluting
coronary stents. In addition, Prof. Rothman has led cardiac
stem cell research for heart failure treatment. He also established
the largest heart attack center in Europe. During
his tenure at the London Chest Hospital, Prof. Rothman
developed a nationally and internationally recognized training
program for interventional cardiology, a medical specialty
that treats patients with heart disease through minimally
invasive techniques such as angioplasty and transcatheter
valves. Prof. Rothman has contributed significantly to
advancing the specialty’s medical education, including
the development of live case demonstrations, which enable
clinicians to learn through observation and interaction
with the physicians performing the procedures. Under his
leadership of this training program, the London Chest Hospital
has trained more than 500 interventional cardiologists
each year. More than one-third of practicing interventional
cardiologists in the U.K. have been trained by Prof. Rothman. Prof.
Rothman has also contributed to the development of
innovative medical technology for interventional cardiology.
In 1985 he created his first start-up company, which
developed intravascular ultrasound technology to enable
clinicians to see inside their patients’ arteries.
He sold the company in May 2000. Intravascular ultrasound
is now routinely used in clinical research and practice. The CardioVascular business at Medtronic is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through collaboration with leading clinicians, researchers and scientists worldwide. About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology – alleviating
pain, restoring health and extending life for millions of people
around the world. Any
forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic’s Annual Report on Form
10-K for the year ended April 24, 2009. Actual results may
differ materially from anticipated results.
Source: Medtronic,
Inc.
|